Navigation Links
Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
Date:9/4/2013

DEERFIELD, Ill. and OSAKA, Japan, Sept. 4, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Priority Review status for the Biologics License Application (BLA) for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis. A BLA was submitted in June 2013 seeking approval for vedolizumab for the treatment of adults with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC). The application submitted for vedolizumab for the treatment of adults with moderately to severely active CD will be reviewed by the FDA under the standard review timeline.  

An application can receive Priority Review designation if it is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. Priority Review status allows for an eight month review period from the date of submission, compared to the standard review period of 12 months.

"Additional treatment options are needed for ulcerative colitis, and the acceptance for Priority Review of vedolizumab underscores this need," said Karen Lasch, M.D., medical director - GI, Medical Affairs, U.S. Region, Takeda. "Takeda is excited about the potential for vedolizumab and, if approved, the possibility of providing a new treatment option for people with CD and UC."

CD and UC are the two most common types of inflammatory bowel disease (IBD), and can be both painful and debilitating, sometimes leading to serious complications. While CD and UC treatment options are available, many patients may not achieve or maintain remission of their disease. 
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. New Data for Abbotts Investigational High Sensitive Troponin Test Shows It May Help Doctors Predict Heart Attack Risk
4. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
5. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
6. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
7. Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function
8. Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
9. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
10. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
11. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Commonwealth Cornerstone Group (CCG) today announced the completion of ... to help fund the expansion and consolidation of healthcare services ... . PHN is the largest federally ... It is the largest employer in Sharon,s ... staff. Currently, PHN Sharon offers scattered services out ...
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... FLINT, Mich. , Dec. 24, 2014  Diplomat ... largest independent specialty pharmacy, is proud to announce ... and quality at Diplomat, will take office as the ... 2015. The formal induction ceremony will take place Feb. ... which will be held at the Renaissance Center in ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3
... Sponsor of ZENPEP(R) CF Cycle for Life , ... , May 3 Thousands of cyclists will take to the streets this summer ... the country to support research to find new therapies and a cure for cystic fibrosis. The ... June 26 . , , , ...
... May 2 Althea Technologies, Inc., ... and manufacturing announced today that it has acquired ... The IP portfolio includes, among other things, Altus, ... injectable technologies.  Applications of this protein crystal technology ...
Cached Medicine Technology:Cystic Fibrosis Foundation Launches National Cycling Series to Benefit Critical Research and Care 2Cystic Fibrosis Foundation Launches National Cycling Series to Benefit Critical Research and Care 3Althea Technologies Acquires Altus Pharmaceuticals'(R) Assets and IP Portfolio, Establishing Technology Platform for Protein Formulations. 2
(Date:12/24/2014)... 2014 Epigenetics finds applications in a ... oncology, drug discovery, developmental biology, and research for metabolic ... of the most widely used techniques for the discovery ... prevalence of cancer is rapidly growing worldwide. In 2012, ... cancer deaths, and 32.6 million people living with cancer ...
(Date:12/24/2014)... New studies reveal that women under the ... depression (March 6, 2014, JAMA Otolaryngology*). And although many people ... 50 percent according to recent polls) facing hearing loss head ... person feels and relates to the world. People who have ... made by way of:, , self-confidence , ...
(Date:12/24/2014)... 25, 2014 Today, Yunx.co.uk, a hot ... dresses and other special occasion outfits, unveils 65 ... are offered at discounted prices, up to 80% off. ... ladies with their fashionable designs, gorgeous looks and delicate ... The business is devoted to designing and offering high-quality ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay ... for one year will be allowed to donate blood in the ... 31-year ban on donations from men who have sex with men. ... to release a new draft guidance in early 2015 that would ... The FDA is changing its policy based on data from other ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- Adults who experienced ... of migraine headaches, suggests a study published online ... "Childhood maltreatment can have long-lasting effects, like ... adulthood," study author Dawn Buse, director of behavioral ... City, said in a journal news release. ...
Breaking Medicine News(10 mins):Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:Abuse in Childhood Tied to Migraines in Adulthood 2
... News) -- The incidence of head and neck cancers related ... States, with the greatest increase among middle-aged white men, a ... risk factors for head and neck cancers, but the sexually ... well, according to researchers from the Louisiana State University Health ...
... Long-term follow-up of a phase II clinical trial ... non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic ... Annual Meeting 2012, held March 31 - April 4. ... to show unusually long survival in some patients," said ...
... Awakening from anesthesia is often associated with an ... restoration of awareness and orientation to one,s surroundings. ... consciousness emerges first. Using brain imaging techniques in ... Adjunct Professor Harry Scheinin, M.D. from the University ...
... (Boston) - Anurag Singh, PhD, assistant professor in ... Boston University School of Medicine has been invited ... for colon cancer at the American Association of ... Singh,s seminar, scheduled for Tuesday April 3rd, will ...
... , TUESDAY, April 3 (HealthDay News) -- Weight ... girls, self-esteem, according to a new study. "We found ... of obesity continued to see themselves as fat, despite changes ... associate professor of sociology at Purdue University in West Lafayette, ...
... Removing a lipoprotein receptor known as SR-BI may help ... presented at the American Association for Cancer Research Annual ... In vitro and mouse studies revealed that depletion of ... cell growth. SR-BI is a receptor for high-density ...
Cached Medicine News:Health News:HPV-Related Head, Neck Cancers on the Rise 2Health News:Scientists solving the mystery of human consciousness 2Health News:Scientists solving the mystery of human consciousness 3Health News:For Many Girls, Slimming Down Doesn't Help Self-Esteem 2Health News:Eliminating the 'good cholesterol' receptor may fight breast cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: